Division of Cardiothoracic Anesthesiology, Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, Tenn.
Department of Statistics, Walker Bioscience, Carlsbad, Calif.
J Thorac Cardiovasc Surg. 2019 Apr;157(4):1545-1553.e5. doi: 10.1016/j.jtcvs.2018.08.090. Epub 2018 Sep 26.
Tissue inhibitor of metalloproteinases 2 (TIMP-2) and insulin-like growth factor-binding protein 7 (IGFBP7) are postoperative urinary biomarkers of renal stress and acute kidney injury (AKI). We conducted this study to test the hypothesis that intraoperative concentrations of urinary [TIMP-2]·[IGFBP7] are associated with postoperative AKI.
We measured urinary [TIMP-2]·[IGFBP7] at 8 perioperative timepoints in 400 patients who participated in a randomized controlled trial of atorvastatin for AKI in cardiac surgery. We compared [TIMP-2]·[IGFBP7] between subjects who did and did not develop KDIGO stage 2 or 3 AKI within 48 hours of surgery, adjusted for AKI risk factors.
Fourteen patients (3.5%) met the primary endpoint of stage 2 or 3 AKI within 48 hours of surgery, and an additional 77 patients (19.3%) developed stage 1 AKI. Patients who developed stage 2 or 3 AKI displayed bimodal elevations of [TIMP-2]·[IGFBP7], with a first elevation (median, 0.45 [ng/mL]/1000) intraoperatively and a second elevation (1.45 [ng/mL]/1000) 6 hours postoperatively. Patients who did not develop AKI did not have any elevations in [TIMP-2]·[IGFBP7]. Each 10-fold increase in intraoperative [TIMP-2]·[IGFBP7] was independently associated with a 290% increase in the odds of stage 2 or 3 AKI (P = .01), and each 10-fold increase in the 6 hours postoperative [TIMP-2]·[IGFBP7] was independently associated with a 650% increase in the odds of stage 2 or 3 AKI (P < .001). The maximum [TIMP-2]·[IGFBP7] between these 2 timepoints provided an area under the receiver operating characteristic curve of 0.82 (95% confidence interval [CI], 0.73-0.90), 100% sensitivity, and 100% negative predictive value using the >0.3 cutoff to predict stage 2 or 3 AKI.
Intraoperative elevations of [TIMP-2]·[IGFBP7] can predict moderate or severe AKI and could provide an opportunity to alter postoperative management to prevent kidney injury.
组织金属蛋白酶抑制剂 2(TIMP-2)和胰岛素样生长因子结合蛋白 7(IGFBP7)是术后肾脏应激和急性肾损伤(AKI)的尿生物标志物。我们进行这项研究是为了检验术中尿[TIMP-2]·[IGFBP7]浓度与术后 AKI 相关的假设。
我们在参加他汀类药物预防心脏手术 AKI 的随机对照试验的 400 名患者中,在 8 个围手术期时间点测量了尿[TIMP-2]·[IGFBP7]。我们比较了术后 48 小时内发生 KDIGO 2 或 3 期 AKI 和未发生 AKI 的患者的[TIMP-2]·[IGFBP7],并进行了 AKI 风险因素调整。
14 名患者(3.5%)在术后 48 小时内达到 2 或 3 期 AKI 的主要终点,另有 77 名患者(19.3%)发生 1 期 AKI。发生 2 或 3 期 AKI 的患者出现[TIMP-2]·[IGFBP7]的双峰升高,术中首次升高(中位数,0.45[ng/mL]/1000),术后 6 小时再次升高(1.45[ng/mL]/1000)。未发生 AKI 的患者的[TIMP-2]·[IGFBP7]没有任何升高。术中[TIMP-2]·[IGFBP7]每增加 10 倍,发生 2 或 3 期 AKI 的几率增加 290%(P=.01),术后 6 小时[TIMP-2]·[IGFBP7]每增加 10 倍,发生 2 或 3 期 AKI 的几率增加 650%(P<.001)。这两个时间点之间的[TIMP-2]·[IGFBP7]最大值提供了 0.82(95%置信区间[CI],0.73-0.90)的接收者操作特征曲线下面积,100%的敏感性和 100%的阴性预测值,使用>0.3 作为截点来预测 2 或 3 期 AKI。
术中[TIMP-2]·[IGFBP7]的升高可以预测中度或重度 AKI,并为改变术后管理以预防肾脏损伤提供机会。